Clinical chemistry tells you if your cholesterol is high. Molecular diagnostics tells you if you have a genetic mutation that causes cancer. The in vitro diagnostics market research shows that molecular diagnostics is the fastest‑growing test type, with a CAGR above 7%. Why? Because of precision medicine. Instead of one size fits all drugs, we're tailoring treatments to your DNA.
What's driving growth? Oncology is a huge application. Liquid biopsies — blood tests that detect cancer DNA — are replacing invasive tissue biopsies. The IVD market trends highlight that the fastest‑growing end‑user is diagnostic laboratories, as hospitals outsource complex molecular tests to specialised labs.
What's new? Next‑generation sequencing (NGS) for infectious disease surveillance. During the pandemic, NGS was used to track variants in real time.
The bottom line: molecular diagnostics is the future. If you're a patient, ask your doctor about genetic testing for cancer or heart disease. If you're an investor, watch this space — it's growing fast.
